Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5689964 | Kidney International Supplements | 2017 | 7 Pages |
Abstract
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Vlado Perkovic, Jonathan C. Craig, Worawon Chailimpamontree, Caroline S. Fox, Guillermo Garcia-Garcia, Mohammed Benghanem Gharbi, Meg J. Jardine, Ikechi G. Okpechi, Neesh Pannu, Benedicte Stengel, Katherine R. Tuttle, Katrin Uhlig, Andrew S. Levey,